Physician profile
Amil Patel
NPI 1952588394
$7,016.80
in general payments reported to CMS, 2019-2025
39 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $728 · 2021: $1,216 · 2022: $991 · 2023: $1,003 · 2024: $1,283 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313 · Education: $17.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.47 |
| Education | $17.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,948.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $687.26 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $377.28 | 2019-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.70 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $322.08 | 2019-2025 | |
| Lilly USA, LLC | $317.67 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $299.78 | 2019-2024 | Ocaliva |
| Pfizer INC. | $272.67 | 2019-2025 | |
| Celgene Corporation | $211.27 | 2021-2024 | Zeposia |
| Genzyme Corporation | $210.09 | 2023-2025 | |
| Daiichi Sankyo INC. | $200.58 | 2019-2025 | Injectafer |
| Ardelyx, INC. | $193.92 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $155.14 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $150.07 | 2023-2025 | Voquezna |
| Medtronic, INC. | $140.23 | 2021-2025 | Interstim |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $125.60 | 2020-2022 | |
| Amgen INC. | $115.17 | 2020-2022 | |
| Madrigal Pharmaceuticals | $112.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $108.16 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $107.99 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $95.84 | 2020-2023 | Dificid |
| Qol Medical, LLC | $66.88 | 2021-2024 | Sucraid |
| Evoke Pharma, INC. | $66.06 | 2021-2023 | Gimoti |
| Braintree Laboratories, INC. | $51.87 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $43.51 | 2024-2025 | Iqirvo |
| Organon LLC | $39.05 | 2021-2025 | Renflexis, Hadlima |
| Ucb, INC. | $36.76 | 2019 | |
| Redhill Biopharma INC. | $35.57 | 2021 | |
| Fresenius Kabi USA, LLC | $28.98 | 2023 | Idacio |
| Echosens North America, INC. | $21.50 | 2020 | |
| Mauna Kea Technologies, INC. | $19.92 | 2024 | |
| Celltrion USA INC. | $17.96 | 2024 | Zymfentra |
| Vivus LLC | $17.20 | 2021 | |
| Exact Sciences Corporation | $16.64 | 2025 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $14.70 | 2020 | |
| Ethicon US, LLC | $13.16 | 2022 | |
| Allergan, INC. | $13.04 | 2019 | |
| Shionogi INC | $12.93 | 2019 | |
| Alfasigma USA, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.